Microbiological screening of compounds with potential anti-lep activity among new synthesis compounds of the pyrimidine series

Aim: To study the effect of new synthesized pyrimidine derivatives on the growth of Mycobacterium lufu (M. lufu) and Mycobacterium tuberculosis (M. tuberculosis) when cultivated on Shkolnikova’s medium.
Materials and methods. The objects of research were new synthesized derivatives of 6 samples of derivatives of pyrimidine - 5-(arylmethylidene)-2,4,6-pyrimidine-2,4,6(1H,3H,5H)-trions under laboratory codes TAG1, TAG2, TAG3, TAG4, TAG5, TAG6 and 7 samples of 5-(getarylmethylidene)-2,4,6-pyrimidine-2,4,6(1H, 3H, 5H)-trions under the laboratory codes TAG7, TAG8, TAG9, TAG10, TAG11, TAG12, TAG13. M. lufu and M. tuberculosisH37Rv strains were used as test cultures. The antimycobacterial activity of the studied compounds was studied by the method of serial dilutions.
Research results. All studied compounds were found to exhibit antimycobacterial activity. The greatest inhibitory effect against M. lufu was noted for TAG1, TAG4, TAG7, TAG12, and TAG13, which was comparable to that of the reference drug dapsone. By the nature of the inhibitory effect on the growth of M. tuberculosis, the compounds under the laboratory codes TAG 1, TAG 4, TAG 7 and TAG13 were comparable to isoniazid, and the effect of the TAG3 compound was even slightly superior to the reference drug.
Conclusion. Among the studied new synthesized pyrimidine derivatives, compounds under the laboratory codes TAG1, TAG4, TAG 7 and TAG13 have the most pronounced antimicrobial activity both against M. lufu and M. tuberculosis, which allows us to consider them as the most promising substances for further research on the search for antimycobacterial, including antileprosy drugs.

1. World Health Organization. Regional Office for South-East Asia. На пути к нулевым показателям лепры. Глобальная стратегия по борьбе с лепрой ( болезнь Хансена) на 2021–2030 гг.. World Health Organization, Regional Office for South-East Asia; 2021:30. URL: https://apps.who.int/iris/handle/10665/342171 (19.12.2022).

2. Faget G.H., Pogge R.C., Johansen F.A., Dinan J.F., Prejean B.M., Eccles C.G. The promin treatment of leprosy: a progress report. Public Health Reports. 1943;58(48):1729–1741. DOI: 10.2307/4584691.

3. Khrykov G.A. Further observation of the effect of sulfone preparations on the leprosy process. Collection of Works on Leprosy. Nukus; 1957(1):83–89. (In Russ.).

4. Noordeen S.K. History of chemotherapy of leprosy Clinics in Dermatology. 2016;34(1):32-36. DOI: 10.1016/j.clindermatol.2015.10.016.

5. Kubanov A.A., Karamova A.E., Vorontsova A.A., Kalinina P.A. Pharmacotherapy of leprosy. Bulletin of dermatology and venereology. 2016;92(4):12-19. (In Russ.). DOI: 10.25208/0042-4609-2016-92-4-12-19.

6. Kar H.K., Gupta R. Treatment of leprosy. Clinics in Dermatology. 2015;33(1):55-65. DOI: 10.1016/j.clindermatol.2014.07.007.

7. Samotrueva M.A., Tsibizova A.A., Yasenyavskaya A.L., Ozerov A.A., Tyurenkov I.N. Pharmacological activity of pyrimidine derivatives. Astrakhan Medical Journal. 2015;10(1):12–29. (In Russ.). URL: https://cyberleninka.ru/article/n/farmakologicheskaya-aktivnost-proizvodnyh-pirimidinov (19.12.2022).

8. Khrapova A.V., Saroyants L.V., Yushin M.Y., Zukhairaeva A.S., Velikorodov A.V. Prospects of using pharmacologically active compounds for the creation of antimycobacterial drugs. Pharmaceutical Chemistry Journal. 2022;55(10):1108–1114. DOI: 10.1007/s11094-021-02544-4.

9. Shmalenyuk E.R., Chernousova L.N., Karpenko I.L., Kochetkov S.N., Smirnova T.G., Andreevskaya S.N. et al. Inhibition of Mycobacterium Tuberculosis strains H37Rv and MDR MS-115 by a new set of C-5 modified pyrimidine nucleosides. Bioorg. Med. Chem. 2013;21(17):4874–4884. DOI: 10.1016/j.bmc.2013.07.003.

10. Khandazhinskaya A.L., Alexandrova L.A., Matyugina E.S., Solyev P.N., Efremenkova O.V., Buckheit K.W. et al. Novel 5'-norcarbocyclic pyrimidine derivatives as antibacterial agents. Molecules. 2018;23(12):3069. DOI: 10.3390/molecules23123069.

11. Yushin M.Yu., Ayupova A.K., Tyrkov A.G., Ilyasov F.K. Effect of 5-(Arylmethylidene)-2,4,6-pyrimidine-2,4,6(1H,3H,5H)-tiones on the course of experimental leprosy infection. Pharmaceutical Chemistry Journal. 2022;55(10):1019–1022. DOI: 10.1007/s11094-021-02531-9.

12. Yushin M.Yu., Tyrkov A.G., Saroyants L.V., Gabitova N.M., Khrapova A.V., Genatullina G.N. et al. Synthesis and antimicobacterial activity of 5-(hetarylmethylidene)-2,4,6-pyrimidine-2,4,6(1H,3H,5H)-triones and 5-(2 chloropropylidene)-2,4,6-pyrimidine-2,4,6(1H,3H,5H)-triones. Pharmaceutical Chemistry Journal. 2020;54(2):134–137. DOI: 10.1007/s11094-020-02169-z.

13. Menshikov V.V., Ankirskaya A.S., Bekhalo V.A., Boytsov A.G., Bondarenko V.M., Dekhnich A.V. et al. Methods of clinical laboratory research. Volume III. Clinical microbiology. М.: Labora; 2009:880. (In Russ.).

14. Tepper E.Z., Shilnikova V.K., Pereverzeva G.I. Microbiology workbook. M.: Drofa; 2004:256. (In Russ.).